flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 in Patients with Obesity-Related Heart Failure and Type 2 Diabetes Kidney Outcomes With Glucagon-Like Peptide-1
Description
The 72-week STEP UP trial randomized 1407 adults with obesity (body mass index [BMI] of 30 or higher) without diabetes to once-weekly subcutaneous semaglutide 7.2 mg, 2.4 mg, or placebo in a 5:1:1 ratio
We see it with insulin
doi: 10.1210/clinem/dgaa202
Pero entre la informacin que circula en redes sociales y las recomendaciones entre amigos, hay mucha confusin
First, choose an injection site
This unique combination sets Retatrutide apart from its predecessors, like Tirzepatide, which primarily focuses on single or dual agonist pathways
